Protagenic Therapeutics, Inc.\new annual operating cash flow
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Operating Cash Flow Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's operating cash flow was −$2.8M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$2.8M | −$1.0M | — |
| 2025 | 2025-03-31 | −$1.8M | — | — |
| 2024 | 2024-12-31 | −$4.2M | −$512,741 | — |
| 2023 | 2023-12-31 | −$3.7M | −$1.7M | — |
| 2022 | 2022-12-31 | −$2.0M | $804,800 | — |
| 2021 | 2021-12-31 | −$2.8M | −$1.4M | — |
| 2020 | 2020-12-31 | −$1.3M | −$860,789 | — |
| 2019 | 2019-12-31 | −$487,990 | $583,198 | — |
| 2018 | 2018-12-31 | −$1.1M | $308,901 | — |
| 2017 | 2017-12-31 | −$1.4M | −$239,770 | — |
| 2016 | 2016-12-31 | −$1.1M | −$758,978 | — |
| 2015 · Dec 31 | 2015-12-31 | −$381,341 | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$378,000 | $412,000 | — |
| 2014 | 2014-06-30 | −$790,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly operating cash flow
Q3.11
Q3.11
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$944,298 | $806,843 | — |
| Q4 2026 | 2026-03-31 | $265,533 | $1.3M | — |
| Q3 2026 | 2025-12-31 | −$509,667 | −$156,027 | — |
| Q2 2026 | 2025-09-30 | −$811,525 | −$494,090 | — |
| Q1 2026 | 2025-06-30 | −$1.8M | −$1.5M | — |
| Q4 2025 | 2025-03-31 | −$1.1M | $591,168 | — |
| Q4 2024 | 2024-12-31 | −$353,640 | $790,794 | — |
| Q3 2024 | 2024-09-30 | −$317,435 | $338,331 | — |
| Q2 2024 | 2024-06-30 | −$246,433 | $1.3M | — |
| Q1 2024 | 2024-03-31 | −$1.7M | −$1.3M | — |
| Q4 2023 | 2023-12-31 | −$1.1M | −$963,498 | — |
| Q3 2023 | 2023-09-30 | −$655,766 | −$120,533 | — |
| Q2 2023 | 2023-06-30 | −$1.5M | −$684,662 | — |
| Q1 2023 | 2023-03-31 | −$371,834 | $58,731 | — |
| Q4 2022 | 2022-12-31 | −$180,936 | $224,153 | — |
| Q3 2022 | 2022-09-30 | −$535,233 | $540,202 | — |
| Q2 2022 | 2022-06-30 | −$847,080 | −$136,697 | — |
| Q1 2022 | 2022-03-31 | −$430,565 | $177,142 | — |
| Q4 2021 | 2021-12-31 | −$405,089 | −$84,221 | — |
| Q3 2021 | 2021-09-30 | −$1.1M | −$557,621 | — |
| Q2 2021 | 2021-06-30 | −$710,383 | −$564,692 | — |
| Q1 2021 | 2021-03-31 | −$607,707 | −$243,301 | — |
| Q4 2020 | 2020-12-31 | −$320,868 | −$171,448 | — |
| Q3 2020 | 2020-09-30 | −$517,814 | −$456,050 | — |
| Q2 2020 | 2020-06-30 | −$145,691 | −$64,900 | — |
| Q1 2020 | 2020-03-31 | −$364,406 | −$168,391 | — |
| Q4 2019 | 2019-12-31 | −$149,420 | $158,372 | — |
| Q3 2019 | 2019-09-30 | −$61,764 | $97,868 | — |
| Q2 2019 | 2019-06-30 | −$80,791 | $263,964 | — |
| Q1 2019 | 2019-03-31 | −$196,015 | $62,994 | — |
| Q4 2018 | 2018-12-31 | −$307,792 | $109,226 | — |
| Q3 2018 | 2018-09-30 | −$159,632 | $199,163 | — |
| Q2 2018 | 2018-06-30 | −$344,755 | −$97,876 | — |
| Q1 2018 | 2018-03-31 | −$259,009 | $98,388 | — |
| Q4 2017 | 2017-12-31 | −$417,018 | −$75,210 | — |
| Q3 2017 | 2017-09-30 | −$358,795 | −$62,727 | — |
| Q2 2017 | 2017-06-30 | −$246,879 | $198,173 | — |
| Q1 2017 | 2017-03-31 | −$357,397 | −$300,006 | — |
| Q4 2016 | 2016-12-31 | −$341,808 | −$235,808 | — |
| Q3 2016 | 2016-09-30 | −$296,068 | −$194,068 | — |
| Q2 2016 | 2016-06-30 | −$445,052 | −$386,567 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$57,391 | −$48,390 | — |
| Q4 2015 | 2015-12-31 | −$106,000 | $5,000 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$102,000 | −$22,000 | — |
| Q4 2015 | 2015-06-30 | −$58,485 | $28,515 | — |
| Q3 2015 | 2015-03-31 | −$9,001 | $106,999 | — |
| Q2 2015 | 2014-12-31 | −$111,000 | $40,000 | — |
| Q1 2015 | 2014-09-30 | −$80,000 | $356,000 | — |
| Q4 2014 | 2014-06-30 | −$87,000 | — | — |
| Q3 2014 | 2014-03-31 | −$116,000 | — | — |
| Q2 2014 | 2013-12-31 | −$151,000 | — | — |
| Q1 2014 | 2013-09-30 | −$436,000 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | −$74,000 | $3.3M | — |
| Q3 2011 · Sep 30 | 2010-09-30 | −$3.4M | — | — |
Protagenic Therapeutics, Inc.\new operating cash flow trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's operating cash flow decreased from −$790,000 to −$2.8M, a change of −$2.0M. The latest reported quarter, Q1 2027, shows −$944,298.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗